S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?

Finch Therapeutics Group (FNCH) Competitors

$2.24
+0.22 (+10.86%)
(As of 04/15/2024 ET)

FNCH vs. KRBP, ALBT, PALI, NSTGQ, GMDA, SRNE, ELOX, ACOR, FRTX, and TTNP

Should you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Kiromic BioPharma (KRBP), Avalon GloboCare (ALBT), Palisade Bio (PALI), NanoString Technologies (NSTGQ), Gamida Cell (GMDA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), Acorda Therapeutics (ACOR), Fresh Tracks Therapeutics (FRTX), and Titan Pharmaceuticals (TTNP). These companies are all part of the "biological products, except diagnostic" industry.

Finch Therapeutics Group vs.

Kiromic BioPharma (NASDAQ:KRBP) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations, valuation and community ranking.

In the previous week, Finch Therapeutics Group had 2 more articles in the media than Kiromic BioPharma. MarketBeat recorded 3 mentions for Finch Therapeutics Group and 1 mentions for Kiromic BioPharma. Kiromic BioPharma's average media sentiment score of 0.96 beat Finch Therapeutics Group's score of 0.00 indicating that Finch Therapeutics Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kiromic BioPharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Finch Therapeutics Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Finch Therapeutics Group received 9 more outperform votes than Kiromic BioPharma when rated by MarketBeat users. Likewise, 52.63% of users gave Finch Therapeutics Group an outperform vote while only 50.00% of users gave Kiromic BioPharma an outperform vote.

CompanyUnderperformOutperform
Kiromic BioPharmaOutperform Votes
1
50.00%
Underperform Votes
1
50.00%
Finch Therapeutics GroupOutperform Votes
10
52.63%
Underperform Votes
9
47.37%

Kiromic BioPharma has a beta of 2, suggesting that its share price is 100% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kiromic BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

10.9% of Kiromic BioPharma shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 3.3% of Kiromic BioPharma shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kiromic BioPharma has higher earnings, but lower revenue than Finch Therapeutics Group. Kiromic BioPharma is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiromic BioPharmaN/AN/A-$20.95M-$15.07-0.19
Finch Therapeutics Group$110K32.86-$74.75M-$47.67-0.05

Finch Therapeutics Group's return on equity of 0.00% beat Kiromic BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Kiromic BioPharmaN/A N/A -125.75%
Finch Therapeutics Group N/A -136.63%-57.40%

Summary

Finch Therapeutics Group beats Kiromic BioPharma on 9 of the 13 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FNCH vs. The Competition

MetricFinch Therapeutics GroupBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$3.61M$2.60B$4.69B$7.48B
Dividend YieldN/A2.27%5.51%3.96%
P/E Ratio-0.0531.71229.3417.42
Price / Sales32.86324.482,485.6291.09
Price / CashN/A139.5633.0928.18
Price / Book0.163.874.664.26
Net Income-$74.75M-$43.53M$99.71M$210.58M
7 Day Performance0.67%-5.72%-4.41%-4.31%
1 Month Performance-12.13%-4.97%-2.90%-1.37%
1 Year Performance-80.93%11.12%12.53%6.85%

Finch Therapeutics Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KRBP
Kiromic BioPharma
0 of 5 stars
$3.00
flat
N/A-37.1%$3.87MN/A-0.2031
ALBT
Avalon GloboCare
0 of 5 stars
$0.33
+6.5%
N/A-84.2%$3.62M$1.20M0.005Short Interest ↓
Gap Up
PALI
Palisade Bio
2.97 of 5 stars
$0.38
-2.5%
$8.75
+2,188.2%
-85.5%$3.55M$250,000.00-0.2112Stock Split
Positive News
NSTGQ
NanoString Technologies
0 of 5 stars
$0.10
-9.5%
N/AN/A$4.57M$127.26M-0.03550Positive News
Gap Down
GMDA
Gamida Cell
1.2269 of 5 stars
$0.04
+29.4%
$4.75
+10,695.5%
-98.9%$4.65M$1.78M-0.07143Gap Up
High Trading Volume
SRNE
Sorrento Therapeutics
0 of 5 stars
$0.01
flat
N/A-90.7%$4.72M$60.32M0.00799Analyst Report
Gap Down
ELOX
Eloxx Pharmaceuticals
0.2312 of 5 stars
$1.02
flat
$55.00
+5,292.2%
-86.9%$3.20MN/A-0.1118News Coverage
Gap Down
ACOR
Acorda Therapeutics
0 of 5 stars
$2.50
-81.4%
N/AN/A$3.10M$118.57M-0.15111Analyst Report
Short Interest ↓
Gap Down
High Trading Volume
FRTX
Fresh Tracks Therapeutics
0 of 5 stars
$0.89
-1.1%
N/A+48.2%$5.31M$8.01M-0.6313
TTNP
Titan Pharmaceuticals
0 of 5 stars
$7.18
+3.2%
N/A-54.1%$5.39M$560,000.000.004Analyst Report
News Coverage
Gap Up

Related Companies and Tools

This page (NASDAQ:FNCH) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners